marijuana stocks news

Medbox, Inc. (MDBX)

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014
Total Revenue 66   105   173   360  
Cost of Revenue 329 305 1,814 729
Gross Profit (263) (200) (1,640) (369)
Operating Expenses
Research Development 106 62 67
Selling General and Administrative 4,050 6,110 2,277 950
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss (4,313) (6,415) (3,980) (1,386)
Income from Continuing Operations
Total Other Income/Expenses Net (115) (2,354) 497 52
Earnings Before Interest And Taxes (4,434) (9,738) (3,797) (1,348)
Interest Expense
Income Before Tax (4,434) (9,738) (3,797) (1,348)
Income Tax Expense
Minority Interest
Net Income From Continuing Ops (4,434) (9,738) (3,797) (1,348)
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income (4,434) (9,738) (3,797) (1,348)
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares (4,434) (9,738) (3,797) (1,348)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$CARA to Webcast Presentation at the Stifel 2015 Healthcare Conference

Cara Therapeutics to Webcast Presentation at the Stifel 2015 Healthcare Conference Cara…

HEXO Corp. (HEXO) To File Management Information Circular Seeking Shareholder Approval

HEXO To File Management Information Circular Seeking Shareholder Approval for Its New…

CLS Holdings USA , Inc (CLSH) Releases 2019 Year-End Statement for CLS Nevada

CLS Holdings Releases 2019 Year-End Statement for CLS Nevada   CLS Holdings…

$OXIS Begins Enrolling and Treating Patients in FDA Phase 1/Phase 2 Clinical Trial

Oxis Begins Enrolling and Treating Patients in FDA Phase 1/Phase 2 Clinical…